Lenvima Stars As Eisai Ups Profit Outlook After Solid Quarter
Executive Summary
Growing use in liver cancer drives global sales of Lenvima along with the overall performance of Eisai.
You may also be interested in...
Second Biogen/Eisai Antibody Moves AHEAD, In Asymptomatic Alzheimer’s
More progress for partners’ amyloid-targeting antibody portfolio as they look to demonstrate benefit of early intervention in pre-symptomatic disease in new collaborative Phase III trial.
Biogen Is Putting Its Money Where Its Mouth Is – Behind The Launch Of Aducanumab
US FDA approval of the Alzheimer's drug may be uncertain, but Biogen will be investing substantially behind a commercial buildout this year.
First In 10 Years, But Lenvima's First-Line Liver Label Could Be Challenged Soon
Eisai and Merck won the first US FDA approval in 10 years for a first-line hepatocellular carcinoma treatment with Lenvima, but challengers are on the horizon. The companies' recent partnership and plans for combination therapy with Keytruda may defend the drug's standing in liver cancer.